Big Ten CRC News & Events
|
The Cancer Center at Illinois and The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute join Big Ten CRC
|
|
The Big Ten Cancer Research Consortium recently welcomed its two newest members: The Cancer Center at Illinois (CCIL) and The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James).
Located at the University of Illinois at Urbana-Champaign, the CCIL develops new insights, tools, and technologies to fight cancer and moves those advances into clinical practice. The CCIL unites historic campus strengths in basic science and engineering to develop new ways to prevent, diagnose, and treat cancer, enabling people to live cancer-free lives. Read more about CCIL.
Based in Columbus, Ohio, the OSUCCC - James is the only cancer program in the United States that features a National Cancer Institute (NCI)-designated comprehensive cancer center aligned with a nationally ranked academic medical center and a freestanding cancer hospital on the campus of one of the nation's largest public universities. Read more about OSUCCC - James.
|
Wilcox, University of Michigan, lead Big Ten CRC studies in peripheral T-Cell lymphoma
The Big Ten Cancer Research Consortium recently opened two studies for patients with relapsed/refractory peripheral T-cell lymphoma (PTCL). Both studies are led by
Ryan A. Wilcox, MD, PhD, of the University of Michigan Rogel Cancer Center. Dr. Wilcox is a member of the Big Ten CRC's
Lymphoid Malignancies Clinical Trial Working Group.
BTCRC-HEM15-028 is a phase I/II study of ixazomib and romidepsin in relapsed/refractory PTCL.
Read more.
BTCRC-HEM16-085 is a phase II study of nivolumab and the antagonistic CSF-1R monoclonal antibody cabiralizumab (BMS-986227) in patients with relapsed/refractory PTCL.
Read more.
|
Big Ten CRC studies accepted as ASCO poster sessions
Two Big Ten Cancer Research Consortium studies, led by Indiana University Melvin and Bren Simon Cancer Center researchers
Greg Durm, MD (left), and
Shadia Jalal, MD, will be presented during poster sessions at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, May 31 - June 4, in Chicago.
Read more.
Also at ASCO:
The Big Ten CRC will host evening meetings for the Big Ten CRC Foundation, Cancer Center Directors, Steering Committee, and Clinical Trial Working Groups at the Holiday Inn Chicago Mart Plaza River North.
See meeting schedule and directions.
Connect with the Big Ten CRC at
Booth #24118 in the exhibit hall located in McCormick Place South, Hall A.
|
University of Illinois
Cancer Center
Member Feature
Get to know University of Illinois Cancer Center researcher
Ardaman Shergill, MD (left), and learn what UIC researcher
Jeremy Johnson, PharmD, PhD, is discovering about phytochemicals in the mangosteen fruit that can disrupt the function of the androgen receptor, a critical target in prostate cancer.
Read more.
|
Rutgers Cancer Institute
of New Jersey
Member Feature
Get to know Big Ten CRC Steering Committee member and radiation oncologist
Salma Jabbour, MD (left), and learn how the Rutgers Cancer Center of New Jersey is working at the forefront of scientific discovery to advance clinical care in a perspective piece by
Howard S. Hochster, MD, FACP.
Read more.
|
|